Janux Therapeutics JANX Proceeds from Maturities, Prepayments and Calls of Short-Term Investments
Proceeds from Maturities, Prepayments and Calls of Short-Term Investments at other companies
Other financials
Where this comes from
Reported directly by Janux Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments.
The official record: Janux Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Janux Therapeutics's proceeds from maturities, prepayments and calls of short-term investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Janux Therapeutics's proceeds from maturities, prepayments and calls of short-term investments?
- Janux Therapeutics (JANX) reported proceeds from maturities, prepayments and calls of short-term investments of $121.31M in Q1 2026.
- How has Janux Therapeutics's proceeds from maturities, prepayments and calls of short-term investments changed year-over-year?
- Janux Therapeutics's proceeds from maturities, prepayments and calls of short-term investments increased by 287.9% year-over-year, from $31.27M to $121.31M.
- What is the long-term trend for Janux Therapeutics's proceeds from maturities, prepayments and calls of short-term investments?
- Over 4 years (2021 to 2025), Janux Therapeutics's proceeds from maturities, prepayments and calls of short-term investments has grown at a 31.8% compound annual growth rate (CAGR), from $134.15M to $405.28M.